Beam Therapeutics Inc. BEAM
24.27
(0.39)
(1.58%)
as of 25 Sep
- Market cap
- $2.6B
- P/E
- 0.0×
Follow BEAM
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (8.18%) | (5.77%) | (8.11%) | (47.07%) |
+8 more TTM periods Free account |
|
| (6.23%) | (4.48%) | (6.19%) | (33.32%) | ||
ROIC |
(1,599.30%) | (438.41%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(7.24%) | (5.10%) | (6.27%) | (40.37%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(3.57) | (3.72) | (3.64) | (3.44) | |
Free Cash Flow |
(372.77) | (383.84) | (360.05) | (352.36) | |
Capital Expenditures |
(13.39) | (14.11) | (14.95) | (14.18) | |
Piotroski F-Score |
3.00 | 3.00 | 3.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(15.49%) | (14.93%) | (13.90%) | (16.57%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
261.91% | 253.23% | 293.12% | 739.28% | |
Selling, General and Administrative Expense of Revenue |
80.36% | 73.35% | 81.45% | 197.84% | |
Share Based Compensation of Revenue |
52.24% | 52.80% | 67.44% | 186.74% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
4.15 | 5.60 | 4.31 | 0.82 | |
Depreciation/Fixed assets |
0.10 | 0.07 | 0.06 | 0.04 | |
Capex/Depreciation |
(1.41) | (1.87) | (2.36) | (3.00) | |
Revenue per Share |
1.50 | 1.59 | 1.41 | 0.54 | |
Operating CF per Share |
(3.44) | (3.58) | (3.49) | (3.30) | |
Capex per Share |
(0.13) | (0.14) | (0.15) | (0.14) | |
Capex to Sales |
0.09 | 0.09 | 0.11 | 0.25 | |
Net Profit Margin |
(55.45%) | (40.23%) | (57.24%) | (742.45%) |
Columns are period end dates